June 01, 2009
EntreMed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer PatientsMay 15, 2009
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual MeetingMay 06, 2009
EntreMed Reports First Quarter 2009 Financial ResultsMarch 12, 2009
EntreMed Reports Fourth Quarter and Year-End 2008 Financial ResultsFebruary 09, 2009
EntreMed Presents Initial Clinical Results for ENMD-2076December 15, 2008
EntreMed Focuses on Development of ENMD-2076December 09, 2008
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple MyelomaNovember 25, 2008
EntreMed to Present at the New York Society of Security Analysts Industry ConferenceNovember 12, 2008
EntreMed Reports Clinical Program Progress and Company UpdateNovember 10, 2008
EntreMed’s MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical TrialNovember 07, 2008
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare ConferenceNovember 06, 2008
EntreMed Reports Third Quarter 2008 Financial ResultsNovember 03, 2008
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis ModelsOctober 23, 2008
EntreMed’s ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer ModelOctober 10, 2008
EntreMed to Present at BioPartnering Europe ConferenceOctober 02, 2008
EntreMed Announces Stock Listing Transfer to Nasdaq Capital MarketAugust 12, 2008
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase ProgramAugust 06, 2008
EntreMed Reports Second Quarter 2008 Financial ResultsJune 18, 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business DevelopmentJune 13, 2008
EntreMed to Present at the BIO 2008 Annual International Convention
